Medicines and Healthcare products Regulatory Agency (MHRA) announced that the Access Consortium has set 2026 priorities to deepen collaboration and improve regulatory efficiency among its five member countries. Heads of the Australian, Canadian, Singaporean, Swiss and UK authorities met on 30 March 2026, chaired for the first time by MHRA, and endorsed an action plan supporting the GROWTH manifesto with a focus on enhancing work‑sharing. The consortium will develop a shared digital platform to facilitate information sharing and joint regulatory work, aiming to shorten response times to expressions of interest and applications through the Access pathway and accelerate access to safe, effective health products. Partners agreed on a strategic communications approach and early work toward a regulatory reliance model for clinical trials and a new batch‑testing scientists network. MHRA chief executive Lawrence Tallon said the UK will lead the next phase of collaboration, benefiting 150 million patients across member states.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.